Previous 10 | Next 10 |
Gainers: Tonix Pharmaceuticals Holding (TNXP) +60%. Helius Medical Technologies (HSDT) +40%. View (VIEW) +42%. Spark Networks (LOV) +32%. Regencell Bioscience Holdings (RGC) +21%. 180 Life Sciences (ATNF) +20%. Evelo Biosciences (EVLO) +17%. NeuroOne Medical Technologies Corporation (NMTC) +1...
Gainers: Elevation Oncology (ELEV) +20%. Cue Biopharma (CUE) +14%. Evelo Biosciences (EVLO) +13%. GeoVax Labs (GOVX) +13%. Immix Biopharma (IMMX) +9%. Losers: Verrica Pharmaceuticals (VRCA) -58%. PMV Pharmaceuticals (PMVP) -10%. TransMedics (TMDX) ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Short squeeze stocks are trending as the market’s losses only widen Recession fears remain a growing concern amid global economic shortcomings Vertex Energy (NASDAQ: VTNR ) tops this week’s list as ...
Gainers: Data Storage Corporation (DTST) +40%. Indonesia Energy Corporation (INDO) +30%. Harpoon Therapeutics (HARP) +28%. Pulse Biosciences (PLSE) +24%. Praxis Precision Medicines (PRAX) +24%. Xeris Biopharma Holdings (XERS) +24%. Griffon Corporation (GFF) +22%. New Concept Energy (GBR) +20%...
Gainers: Harpoon Therapeutics (HARP) +18%. Grove (GRVI) +11%. NanoViricides NNVC +11%. Travere Therapeutics TVTX +9%. Compass Therapeutics (CMPX) +4%. Losers: Chimerix CMRX -58%. Eliem Therapeutics ELYM -29%. Humacyte (HUMA) -20%. Va...
Eliem Therapeutics press release (NASDAQ:ELYM): Q1 GAAP EPS of -$0.50 beats by $0.06. Cash, cash equivalents and short- and long-term marketable securities was $149.9 million as of March 31, 2022, as compared to $47.9 million as of March 31, 2021. Shares -2.27% PM. For further details see: ...
SEATTLE and CAMBRIDGE, United Kingdom, May 16, 2022 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM), a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epile...
Gainers: Nkarta (NKTX) +84%. ERYTECH Pharma (ERYP) +54%. Sunshine Biopharma (SBFM) +25%. Rubius Therapeutics (RUBY) +17%. Quoin Pharmaceuticals (QNRX) +12%. Losers: Eliem Therapeutics (ELYM) -55%. Clarus Therapeutics Holdings (CRXT) -54%....
Eliem Therapeutics (NASDAQ:ELYM) said a phase 2a trial of ETX-810 to treat diabetic peripheral neuropathic pain did not meet the goal of reducing pain intensity, and that the company has chosen to delay enrollment in studies of ETX-155 in depression. The company said ETX-810 is currently...
Phase 2a clinical trial of ETX-810 in diabetic peripheral neuropathic pain (DPNP) did not achieve the primary endpoint Phase 2a clinical trial evaluating ETX-810 in patients with lumbosacral radicular pain (LSRP) has been fully enrolled with topline data anticipated in the third q...
News, Short Squeeze, Breakout and More Instantly...
Eliem Therapeutics Inc Company Name:
ELYM Stock Symbol:
NASDAQ Market:
Eliem Therapeutics Inc Website:
SEATTLE and CAMBRIDGE, United Kingdom, June 28, 2024 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc . (Nasdaq: ELYM), announced today that the Company will be included in the Russell 2000® Index and the broad-market Russell 3000® Index, as part of the annual reconstitutio...
Eliem to focus on advancing TNT119, an anti-CD19 antibody designed to treat a broad range of autoimmune diseases, including systemic lupus erythematosus, immune thrombocytopenia and membranous nephropathy Post-close cash and cash equivalents of $220 million expected to fund operations i...
2024-06-17 07:14:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...